Trial Profile
A Phase Ib, Open-label, Repeat Dose, Study of EPEG in Beta Thalassemia Patients With Non-transfusion Dependent Thalassemia (β NTDT)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 May 2018
Price :
$35
*
At a glance
- Drugs Recombinant erythropoietin (Primary)
- Indications Beta-thalassaemia
- Focus Adverse reactions
- Sponsors Prolong Pharmaceuticals
- 23 May 2018 Status changed from not yet recruiting to completed.
- 08 Nov 2016 New trial record